Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NociPro
- Development stage
- Preclinical
- Lead developer
- Encoded Therapeutics
- Modality
- Gene Therapies
- Administration
- Intravenous
01
Overview
NociPro is a modality-agnostic promoter platform developed by Encoded Therapeutics for the precise cellular targeting of nociceptor sensory neurons. Designed for use in gene therapy, the platform enables highly targeted and cell-type-selective control of gene expression within the peripheral nervous system. By restricting the expression of therapeutic payloads to specific pain-sensing neurons, NociPro aims to provide a more effective and safer treatment for chronic pain conditions. Preclinical data demonstrating the platform's capabilities were presented at the American Society of Gene & Cell Therapy (ASGCT) conference in May 2026.
- Brand names
- NociPro
Beyond the preview
Go deeper on NociPro.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NociPro.